InflaRx (IFRX) EBIT Margin (2023 - 2026)
InflaRx's (IFRX) quarterly EBIT Margin came in at 17881.53% in Q2 2026, up 1487863.0% year-over-year from N/an in Q2 2025, and down 147.18% quarter-over-quarter from 37898.35% in Q4 2025.
Powered by 
Analysis
InflaRx (IFRX) EBIT Margin (2023 - 2026) Analysis & Trends
InflaRx has disclosed EBIT Margin across 4 years of filings, most recently posting 17881.53% for Q2 2026.
- In Q2 2026, EBIT Margin rose 1487863.0% year-over-year to 17881.53%; the TTM figure through Jun 2026 stood at 54144.47% (down 745489.0% YoY), while the FY2025 annual figure was 164533.84%, down 13256015.0% from the prior year.
- EBIT Margin came in at 17881.53% for Q2 2026 at InflaRx, down from 37898.35% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 12531646.34% in Q4 2024 to a low of 1964483.64% in Q4 2023.
- Average EBIT Margin over 4 years is 924632.91%, with a median of 32760.16% recorded in 2025.
- Year-over-year, EBIT Margin surged 1449612998 bps in 2024 and plunged 1249374799 bps in 2025.
- Over 4 years, EBIT Margin stood at 1964483.64% in 2023, then surged by 738 bps to 12531646.34% in 2024, then tumbled by 100 bps to 37898.35% in 2025, then tumbled by 147 bps to 17881.53% in 2026.
- Per Business Quant data, the three most recent EBIT Margin figures were 17881.53% in Q2 2026, 37898.35% in Q4 2025, and 39769.22% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | -17,881.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17,881.53% |
| Dec 31, 2025 | 37,898.35% |
| Sep 30, 2025 | -39,769.22% |
| Jun 30, 2025 | -32,760.16% |
| Mar 31, 2025 | -36,088.30% |
| Dec 31, 2024 | 12,531,646.34% |
| Sep 30, 2024 | -12,405.24% |
| Jun 30, 2024 | -242,200.14% |
| Mar 31, 2024 | -34,655.19% |
| Dec 31, 2023 | -1,964,483.64% |
| Sep 30, 2023 | -18,339.32% |